Bristol Myers Squibb (BMS) is expanding its direct-to-patient offerings, providing eligible U.S. patients with steeply discounted prices for deucravacitinib (Sotyktu) and apixaban (Eliquis).
Eligible cash-pay patients can now purchase these medicines directly from BMS and significantly lower their out-of-pocket costs.
Beginning January 2026, deucravacitinib will be offered through the new BMS Patient Connect platform, which follows the launch of the Bristol Myers Squibb-Pfizer Alliance program apixaban earlier this month.
The platform will offer deucravacitinib at more than 80% less than the current list price.
“We are proud to now offer Sotyktu at a lower price via BMS Patient Connect, our new direct-to-patient platform designed to make our innovative medicines more accessible and affordable for patients living with serious conditions,” says Christopher Boerner, PhD, Board Chair and CEO of Bristol Myers Squibb, in a news release. “We are taking a leading role in removing barriers, providing transparency and lowering out-of-pocket costs so patients in the United States can get the treatments they need—delivered directly to their door, wherever they are in the country.”
Eligible cash-pay U.S. patients with a deucravacitinib prescription will be able to purchase the medicine via BMS Patient Connect with access to shipping across all 50 states and Puerto Rico and with full transparency into the costs of their medicines. BMS Patient Connect will also provide patient support resources and allow for the addition of other BMS medicines that are appropriate for this model in the future.
